A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours: open-label, non-randomised, multi-centre, dose escalation trial

Trial Profile

A Phase I/Ib Trial of the Oral Hedgehog inhibitor, LY2940680, in Combination with Weekly Paclitaxel in Patients with Platinum-Resistant, Recurrent Ovarian Cancer or Recurrent, Advanced, Solid Tumours: open-label, non-randomised, multi-centre, dose escalation trial

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Taladegib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms HIPROC
  • Most Recent Events

    • 03 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Results of the dose escalation phase (n=11) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 20 Aug 2015 New source identified and integrated (United Kingdom Clinical Research Network:19561)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top